Deana Ferreri, PhD


Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD

March 15, 2025

A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.

Resolution of Injection Site Reactions After Switching to Adalimumab Biosimilar

February 22, 2025

A 15-year-old girl with ulcerative colitis who developed injection site reactions to the adalimumab reference product was successfully switched to the biosimilar LBAL without recurrence of symptoms, demonstrating the safety and effectiveness of switching for medical reasons, likely due to an allergic reaction to an excipient in the originator.

Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

February 08, 2025

A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.

No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar

January 25, 2025

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant differences in lab markers or disease activity between those on Remicade and those switched to biosimilar CT-P13 (Inflectra).

Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease

January 18, 2025

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimliar's FDA approval.

Stable Patient Satisfaction Found After Switching From the Humira or Biosimilar CT-P17

December 14, 2024

A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.